Letter to the Editor. | DOI: https://doi.org/10.31579/2690-1919/264
Rheumatology and Clinical Immunology, Professor of Rheumatology and Clinical Immunology, School of Medicine, Cairo University.
*Corresponding Author: Reem Hamdy A Mohammed. Rheumatology and Clinical Immunology, Professor of Rheumatology and Clinical Immunology, School of Medicine, Cairo University.
Citation: Reem Hamdy A Mohammed. (2022). The EULAR 2022- What Is new? A lesson about Belimumab Therapy and Pregnancy with Autoimmune Rheumatic Diseases, J. Clinical Research and Reports, 11(5) DOI:10.31579/2690-1919/264
Copyright: © 2022 Reem Hamdy A Mohammed. This is an open-access article distributed under the terms of The Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 03 September 2022 | Accepted: 29 September 2022 | Published: 10 October 2022
Keywords: pregnancy; congenital malformations (cm); autoimmune rheumatic diseases
While going through this excellent collection of high-quality scientific abstracts, we get caught by posters discussing safety and efficacy of antirheumatic drugs during pregnancy in mothers with the diagnosis of an autoimmune disease.
The 2022 European League against Rheumatology meeting brought up a series of news and scientific updates that focused on what is new towards best clinical practice in the field of rheumatology. While going through this excellent collection of high-quality scientific abstracts, we get caught by posters discussing safety and efficacy of antirheumatic drugs during pregnancy in mothers with the diagnosis of an autoimmune disease.
There was that interesting abstract by Ghalandari and colleagues [1] of a retrospective cohort study in pregnant patients with systemic lupus erythematosus on belimumab therapy. The cohort was identified through the EudraVigilance database and included all belimumab-exposed pregnancy-related reports, until March 2021, a total of 47 pregnancies, disposing the reported fetal and neonatal outcomes with either scheduled discontinuation of belimumab therapy from the first trimester group A (number= 37) or continuation of therapy group B (number= 10). The authors excluded uninformative and dual reports, non-medical elective abortions and fetal chromosomal abnormalities. The primary outcomes considered included the frequency of live births or deaths due to miscarriage or still birth, the rates of; pre-term birth, low birth weight and major congenital malformations (CMs). The study concluded that there was no statistical difference in fetal death rates between the two groups (46.4% A and 52.4% B , respectively; p-value>0.05), while there was an observable tendency towards increased incidence of pre-term births (43.2% A vs 40% B, P > 0.05) and low birth weight babies (24.35% A, 0.00 % B respectively, P > 0.05) was higher with discontinuation of belimumab in the first trimester though statistically insignificant. [1]
The dilemma of a biologic drug risk versus benefit during pregnancy in patients with systemic lupus erythematosus though of significant relevance to clinical practice remains a matter of great concern due to ethical considerations and paucity of data. In Lupus, the uncontrolled disease activity by itself especially in the presence of lupus nephritis or high damage index might contribute to serious maternal and fetal adverse events. [2,3,4] In this interesting study, the authors concluded that continuation of belimumab in patients already on treatment might contribute to a better pregnancy outcome with an acceptable safety margin. [1] The study though interesting we find ourselves still encountered by the limitation of this small number of patients who continued the drug therapy during pregnancy (10 cases) compared to those schedules for discontinuation (37 cases).
Dear Editorial Team, Clinical Medical Reviews and Reports. My experience with the journal was highly positive. The peer-review process was rigorous, constructive, and completed in a timely manner. The reviewers provided valuable comments that helped improve the quality and clarity of our manuscript. The editorial office was professional, responsive, and supportive throughout all stages of the publication process. Communication was clear and efficient, and any questions were addressed promptly. Overall, I found the journal to maintain high scientific standards and an excellent publication workflow. I would be pleased to consider submitting future work to this journal. Best wishes from, Elena Popa.
It was my pleasure to submit my testimonial concerning the Reviewer Board of our Scientific Journal “Brain and Neurological Disorders”. The Reviewers focused on some modifications and their contribution was helpful. The ladies of our Editorial Office were also supported my efforts. It was my honor to have such a co-operation and I am looking forward for more collaboration.
Dear Grace Pierce, Editorial Coordinator of Journal of Clinical Research and Reports, Thank you for the speedy and efficient peer review process. I appreciate the fact that your peer reviewers do not take months to respond like with some other journals. I would also like to thank the editorial office for responding quickly to my questions. It is an excellent journal. I plan to submit more manuscripts in the future. Best wishes from, Robert W. McGee
Dear Grace Pierce, Editorial Coordinator of Journal of Clinical Research and Reports, Working with you and your team on our recent publication in JCRR has been a truly wonderful and enjoyable experience. The responses were prompt, and the reviewers were patient, constructive, and highly professional. One reviewer in particular gave me the feeling that a professor was carefully reading and commenting on my coursework, which was deeply touching. The entire process was straightforward and hassle‑free, with no tedious online forms to complete. I highly recommend this journal. Best wishes from, DR Aibing Rao, Head of R&D
I Appreciate the Opportunity to Share my Experience with the Journal of Clinical Research and Reports. The peer review process was timely and constructive, and the feedback provided helped improve the quality of our manuscript. The editorial office was professional, responsive, and supportive throughout the process, ensuring smooth communication and efficient handling of the submission. Overall, it was a positive experience collaborating with your team.
Dear Mercy Grace, Editorial Coordinator of Obstetrics Gynecology and Reproductive Sciences, We would like to express our gratitude for your help at all stages of publishing and editing the article. The editors of the magazine answer all the necessary questions and help at every stage. We will definitely continue to cooperate and publish other works in the Obstetrics Gynecology and Reproductive Sciences! Best wishes from, Alla Konstantinovna Politova,
